TY - JOUR T1 - Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer JF - Anticancer Research JO - Anticancer Res SP - 3885 LP - 3889 DO - 10.21873/anticanres.15183 VL - 41 IS - 8 AU - LEANDRO BLAS AU - MASAKI SHIOTA AU - SHIGETOMO YAMADA AU - KOSUKE IEIRI AU - SHOHEI NAGAKAWA AU - SHIGEHIRO TSUKAHARA AU - TAKASHI MATSUMOTO AU - EIJI KASHIWAGI AU - ARIO TAKEUCHI AU - JUNICHI INOKUCHI AU - KEN-ICHIRO SHIGA AU - AKIRA YOKOMIZO AU - MASATOSHI ETO Y1 - 2021/08/01 UR - http://ar.iiarjournals.org/content/41/8/3885.abstract N2 - Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer. ER -